Targeting IL-17 in SLE involves three primary strategies, including direct neutralization with secukinumab or ixekizumab, achieving 63% renal and 73% skin response but with increased infection risk (61, 77), indirect inhibition via CaMK4 and STAT3 blockade, which suppress IL-17A production and reduce proteinuria through H3K27ac modulation (62, 64, 93), and metabolic reprogramming, which decreases renal IL-17+ cells by 61% (94). Here, IL17A is linked to systemic lupus erythematosus.